



Diabetes Medication Metformin Inhibits Osteoclast Formation and Activity in *In Vitro* Models for Periodontitis

Lucy Y. Tao^{1,2†}, Katarzyna B. Łagosz-Ćwik^{3†}, Jolanda M.A. Hogervorst⁴, Ton Schoenmaker¹, Aleksander M. Grabiec³, Tim Forouzanfar⁵, Fridus A. van der Weijden¹ and Teun J. de Vries^{1*}

¹Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije University Amsterdam, Amsterdam, Netherlands, ²Amsterdam University College, University of Amsterdam and Vrije University Amsterdam, Amsterdam, Netherlands, ³Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland, ⁴Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije University Amsterdam, Amsterdam, Netherlands, ⁵Department of Oral and Maxillofacial Surgery and Oral Pathology, Amsterdam UMC, Amsterdam, Netherlands

OPEN ACCESS

Edited by:

Stefania Mariggiò, National Research Council (CNR), Italy

Reviewed by:

Martina Rauner, Technical University Dresden, Germany Rupesh K. Srivastava, All India Institute of Medical Sciences, India

*Correspondence:

Teun J. de Vries teun.devries@acta.nl

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Cell and Developmental Biology

Received: 15 September 2021 Accepted: 13 December 2021 Published: 13 January 2022

Citation:

Tao LY, Łagosz-Ówik KB, Hogervorst JMA, Schoenmaker T, Grabiec AM, Forouzanfar T, van der Weijden FA and de Vries TJ (2022) Diabetes Medication Metformin Inhibits Osteoclast Formation and Activity in In Vitro Models for Periodontitis. Front. Cell Dev. Biol. 9:777450. doi: 10.3389/fcell.2021.777450 Diabetes and periodontitis are comorbidities and may share common pathways. Several reports indicate that diabetes medication metformin may be beneficial for the periodontal status of periodontitis patients. Further research using appropriate cell systems of the periodontium, the tissue that surrounds teeth may reveal the possible mechanism. Periodontal ligament fibroblasts anchor teeth in bone and play a role in the onset of both alveolar bone formation and degradation, the latter by inducing osteoclast formation from adherent precursor cells. Therefore, a cell model including this type of cells is ideal to study the influence of metformin on both processes. We hypothesize that metformin will enhance bone formation, as described for osteoblasts, whereas the effects of metformin on osteoclast formation is yet undetermined. Periodontal ligament fibroblasts were cultured in the presence of osteogenic medium and 0.2 or 1 mM metformin. The influence of metformin on osteoclast formation was first studied in PDLF cultures supplemented with peripheral blood leukocytes, containing osteoclast precursors. Finally, the effect of metformin on osteoclast precursors was studied in cultures of CD14⁺ monocytes that were stimulated with M-CSF and receptor activator of Nf-κB ligand (RANKL). No effects of metformin were observed on osteogenesis: not on alkaline phosphatase activity, Alizarin red deposition, nor on the expression of osteogenic markers RUNX-2, Collagen I and Osteonectin. Metformin inhibited osteoclast formation and accordingly downregulated the genes involved in osteoclastogenesis: RANKL, macrophage colony stimulating factor (M-CSF) and osteoclast fusion gene DC-STAMP. Osteoclast formation on both plastic and bone as well as bone resorption was inhibited by metformin in M-CSF and RANKL stimulated monocyte cultures, probably by reduction of RANK expression. The present study unraveling the positive effect of metformin in periodontitis patients at the cellular level, indicates that metformin inhibits osteoclast formation and activity, both when orchestrated by periodontal ligament fibroblasts and in cytokine driven osteoclast formation assays. The results indicate that

metformin could have a systemic beneficiary effect on bone by inhibiting osteoclast formation and activity.

Keywords: periodontitis, osteoclasts, diabetes, metformin, peridontal ligament

INTRODUCTION

There are indications that diabetes patients have an increased risk of developing periodontitis ((Nascimento et al., 2018; Verhulst et al., 2019). Therefore, common pathogenesis pathways may exist. Periodontitis is the inflammation-related disease. It is characterized by degradation of alveolar bone that surrounds teeth, a process activated by recruited multinucleated osteoclasts. From a pharmacological point of view one could argue that medication that is used for diabetes may also benefit periodontitis patients. Metformin could be such a pleiotropic drug, showing positive effects not only in diabetes, but also in osteoporosis and periodontitis (Ursini et al., 2018). Its principal mode of action is as insulin sensitizer. It lowers the blood sugar level, which makes it a suitable drug for treating diabetes type II patients. It is a biguanid that has been used as an insulin sensitizer for more than 50 years (Halimi, 2006). The last 10 years have shown that metformin could be beneficial in various bone diseases as well, including periodontitis (Chandran, 2017).

Diabetes adversely affects a variety of organ systems in the body, including bones. It diminishes bone-mineral density and therefore weakens bone strength (Bak et al., 2010). When blood glucose levels increase, cartilage quality and quantity decrease (Mannucci and Dicembrini 2015). Diabetes patients have lower bone quality, and metformin may reverse these effects on bone, as shown in preclinical animal studies and clinical applications (Bahrambeigi 2019). It is therefore hypothesized that insulin stimulates osteoblast differentiation and bone matrix synthesis.

A beneficiary effect of metformin on bone has also been studied in periodontitis models (Bak et al., 2010; Araújo et al., 2017; Sun et al., 2017). Bak et al. investigated the effects of metformin on the progression of periodontitis in rats with ligature-induced periodontitis. Metformin reduced inflammatory cell infiltration and alveolar bone loss in periodontal tissues (Bak et al., 2010). This and other findings (Araújo et al., 2017) suggest that low doses of metformin reduce bone loss. Sun et al. found a higher number of osteoclasts in diabetic rats compared to non-diabetic rats (Sun et al., 2017). In the same study, it was shown that metformin decreased the number of osteoclasts compared to untreated diabetic rats (Sun et al., 2017). Gingival fibroblasts, when exposed to lipopolysaccharide (LPS) from periodontopathic bacterium Porphyromonas gingivalis, respond to metformin by severely lowering the expression of inflammatory cytokines IL-6, IL-1β and TNF-α, demonstrating an anti-inflammatory function of metformin (Kang et al., 2017). Calcium phosphate scaffolds with incorporated metformin showed increased osteogenic activity by periodontal ligament fibroblasts, which holds promise for use of metformin in bone regeneration (Zhao et al., 2019). These mouse studies urge extrapolating research using human cell systems on both the bone formation and bone degradation site, hereby elucidating the beneficiary effect of metformin in the human context.

Clinically, metformin has been applied in experimental treatments of periodontitis patients. Metformin was applied in gels at the site of alveolar bone loss. Patients were treated with a gel consisting of 0.5, 1 or 1.5% metformin locally at the site of bone loss. 10 μ L of gel was injected into the periodontal pockets, and during the trial time of 6 months, gingival crevicular fluid was collected for analysis (Pradeep et al., 2013). Comparing all metformin test groups to the control, periodontal parameters significantly improved (Pradeep et al., 2013). Rao et al. treated smokers with chronic periodontitis using 1% metformin gel in a clinical trial (Rao et al., 2013) and showed similar improvements. Subsequent follow-up studies with slight modifications resulted in similar results (Pradeep et al., 2015; Pradeep et al., 2016).

These promising results with metformin in animal studies as well as in clinical studies urge mechanistic insight using a relevant cell system. Periodontal ligament fibroblasts anchor teeth in bone and also play a crucial role in both osteogenesis and osteoclastogenesis, processes that can be elegantly mimicked *in vitro* (De Vries et al., 2017; Ruppeka-Rupeika et al., 2018; De Vries et al., 2019; Karlis et al., 2020; Loo-Kirana R.; Gilijamse M.; Hogervorst J., 2021). Support for the relevance of periodontal ligament fibroblasts comes from an animal study where periodontal ligament fibroblasts were shown to play a key role in alveolar bone regeneration (Ren et al., 2015).

In the present study, we assessed whether metformin has an alleged positive effect on osteogenesis by culturing periodontal ligament fibroblasts in the presence of osteogenic medium and metformin. The effect of metformin on mineralization was assessed by quantifying alkaline phosphatase activity, by staining deposited mineral with Alizarin red staining and by gene expression of osteogenic transcription factor RUNX-2, matrix protein collagen type I and bone matrix protein Osteonectin. The effect of metformin on osteoclastogenesis was assessed in co-cultures of periodontal ligament fibroblasts and peripheral blood mononuclear cells (PBMCs) containing osteoclast precursors. Here, the formation of multinucleated cells was assessed after staining osteoclast characteristic tartrate resistant acid phosphatase (TRAcP) and by counting the nuclei. Since osteoclast-like cells that are formed in these cocultures do not resorb bone (De Vries et al., 2006; Sokos et al., 2015), we further assessed the effect of metformin on osteoclast activity by culturing CD14⁺ monocytes in the presence of M-CSF and RANKL, a cocktail yielding osteoclasts.

MATERIALS AND METHODS

Cell Cultures

The periodontal ligament fibroblasts were isolated from nine different donors who had their wisdom teeth extracted for medical reasons. Sampling from the donors was conducted at Amsterdam University Hospital, location VU University Hospital under supervision of TF. The studies involving human participants were reviewed and approved by the Medische Etische Toetsingscommissie VU Medisch Centrum, Amsterdam, the Netherlands. The teeth containing periodontal ligament fibroblasts were surgical waste control material for osteogenic differentiation of adipose tissue derived stem cells.

All the individuals were informed that the cells retrieved from the surgical waste material was used for research on bone formation and bone degradation. A signed informed consent and samples were coded to guarantee the anonymity of the donors as required by Dutch law. The use of buffy coats from the blood bank (Sanquin, Amsterdam) was under ethical committee number NVT230.01. Researchers handling the fibroblasts (LT, KL-C, TJdV) could not in any way trace back the identity of the donors. Cells were scraped off the middle one third of the root and were propagated until passage three and subsequently frozen in liquid nitrogen. Cells from passage five were used in all experiments.

Osteogenesis and Osteoclastogenesis Assays Using Periodontal Ligament Fibroblasts

Confluent flasks at passage four were trypsinized and cells were seeded at day -1 in 48 wells plates at 1.5.10⁴ cells per well for osteoclastogenesis assays or 3.10⁴ cells per well for osteogenesis assays. At day 0, the start of the experiment, the culture medium was removed from the 48-well plates. For the osteogenesis-assay plates, 0.4 ml mineralisation medium - composed of DMEM, 10% FCI, 1% PSF, 50 µg/ml ascorbic acid (Sigma), 10 nM β -Glycerophosphate (Sigma), and different metformin concentrations (or the solvent volume of sterile water, in the case of 0 mM metformin) were added to the wells. For osteoclastogenesis assays, peripheral blood mononuclear cells (PBMCs) derived from a buffy coat (Sanquin, Amsterdam) were added as source containing osteoclast precursors. ACTA has an agreement with bloodbank Sanquin to use buffy coats for research purposes. Metformin (Sigma Aldrich, D150959) was dissolved in demineralized water and added to cultures in a range between 0 and 1.0 mM, according to concentrations used in the literature.

For the osteoclastogenesis-assay plates, 0.2 ml containing $5 \cdot 10^5$ PBMCs in culture medium were added to the wells as well as 0.2 ml of metformin-consisting medium. During the 21 days duration of the experiment, culture- and mineralization-medium with the appropriate concentration of metformin was replenished twice a week.

DNA Concentration and Alkaline Phosphatase Activity

Cells were harvested at day 0 and day 14 of culturing. In order not to sample dead cells, the adherent cells were washed twice with PBS. Next, they were lysed in 150 μ l MilliQ per well and stored in -20° C. Prior to analysis, the plates underwent three cycles of freeze-thawing. Alkaline phosphatase (ALP) activity was

measured using 4-nitrophenyl phosphate disodium salt (Merck, Darmstadt, Germany) at pH 10.3 as a substrate for ALP according to the method described by Bastidas-Coral (Bastidas-Coral et al., 2016). After incubation of 60 min at 37°C, the reaction was stopped with sodium hydroxide. Absorbance was measured with 405 nm with a Synergy HT spectrophotometer (BioTek Instruments Inc., Winooski, VT). DNA concentration (ng/ml) was measured using CyQuant Cell Proliferation Assay Kit (Molecular Probes, Leiden, Netherlands) mixed with lysis buffer. Fluorescence was measured at 485 nm excitation and 528 nm emission with a Synergy HT spectrophotometer (BioTek Instruments Inc., Winooski, VT, United States). ALP activity was expressed as ALP per DNA (nMol/ng).

Alizarin Red Staining

Alizarin red staining was performed after 14 or 21 days to analyze the mineral deposition. 2% Alizarin red S at pH 4.3 (Sigma-Aldrich) was used for staining. Cells were fixed for 10 min in 4% formaldehyde and rinsed with deionized water before adding 300 μ l of 2% Alizarin solution per well. After incubation of 15 min at room temperature, the cells were washed with deionized water and air-dried. Mineral deposition was visualized as red nodules.

Quantitative Polymerase Chain Reaction

Quantitative polymerase chain reaction (qPCR) analysis was performed for osteogenesis and osteoclastogenesis at day 0 and 14 or 21. At these time points the culture medium was removed and 200 µl RNA lysis buffer (Qiagen, Hilden, Germany) was added per well. Subsequently, the 48-well plates were stored at -80° C until further use. RNA isolation was performed with Qiagen RNeasy Mini kit according to the manufacturer's instructions. The RNA concentration and quality was determined using absorption read at 260 and 280 nm with Synergy HT spectrophotometer (BioTek Instruments Inc., Winooski, VT). RNA was reverse transcribed to cDNA with the MBI Fermentas cDNA synthesis Kit (Vilnius, Lithuania). Oligo(dT) 18 and D(N)6 were used as primers. Real time primers were designed for several genes. PCR was performed on the LC480 light cycler (Roche, Basel, Switzerland). Beta-2-microglobulin (B2M) was used as a housekeeping gene for the osteogenesis markers, while hypoxanthine phosphoribosyltransferase 1 (HPRT1) was used as housekeeping gene for the osteoclastogenesis and osteoclast makers. Gene expression was normalized for $\beta 2M$ or HPRT1 expression following the comparative threshold (Ct) method. ΔC (Ct gene of interest - Ct housekeeping gene) was calculated and relative expression of the genes was determined as $2^{-\Delta Ct}$. The primer sequences are listed in Table 1.

TRAcP Staining and Osteoclast Counts

Plates for detecting tartrate resistant acid phosphatase (TRAcP) activity staining were harvested in duplicate on t = 21. Cells were washed with PBS and fixed with 4% PBS buffered formaldehyde for 10 min before being stored with PBS at 4°C. After washing the cells with water at 37°C, TRAcP staining solution was made consisting of Fast Garnet GBC base, sodium nitrate, acetate, naphthol AS-BI and tartrate in AD on 37°C, using the leukocyte acid phosphate kit (Sigma) following the

TABLE 1 | primers used.

Hessekeeping gene HPRT Prof Science Prof Prof Science Prof Prof Prof Prof Prof Prof Prof Prof	Genes	Primer sequence 5'-3'	Amplicon length (bp)	ENSEMBL gene ID
HPRT Fv TQACCTTQATTIATTIGGATACC 101 ENSG0000165704 Rv CGAQGAQGAQAGQGTTGAGTCCT 100 ENSG000016225 E2M Fv CGAQGAQGCAQACQAAQCT 156 ENSG0000124813 RUNX2 Fv CCAACAqACCAQAAQCT 156 ENSG0000124813 Collagen 1 Fv TCCAACQAATCCC Goteonectin Fv AqCCQAATTCCTgqTC 7 Costeonectin Fv AQCCQAATTCCTgqTC 67 ENSG0000148521 RANK Fv CCTgqACCACTGTACTCCT RANK Fv CCTgqACCACTGTACCTCCT RV AgggTaCCAQqACGTTCTG 60 ENSG0000141655 RANK Fv CCTgqACCACTGTACCTCCT RV AgggTaCCAQqAQGTTCTCGT 60 ENSG0000164761 Fv AQCCQAATTCCCGATCATA Fv QCCCAACCQGTCATATCC 100 ENSG0000164761 Fv AQCCQAATTCCTGTT 60 ENSG0000164761 Fv AQCCQAATTCCTGTT 7 RANK Fv CCTGQACCACTGTACCTCCT RV ACQCGCTCGGTTCCCTAA Fv GCCAACCCQATCCTGGTTCCCT RV ACQCGCATCGQATTCCTGT 7 Costeonectin Fv AQCGQAATGCCGATCATA Fv GCCCAACCCGATCATA Fv GCCAACCCGATCGTGTTCCCT RV ACQCGCATCGQATTCCTGT 100 ENSG0000164761 FV ACQCGACTCGGATCATG COSTAMP Fv CTGQCQCTCGTGTTTC Fv AATTGTQGCAQAGGTTCTTGCT TRACP Fv CCGAGGCAGTACACGTCCACAGTC TRACP Fv CCGAGGCAGTACCGCAACGTTC TRACP Fv CCCAACCCGATCAT FV GCCAATCCGGCAACTTGACTTCCT TRACP Fv CCCAATGTGGAACGTTCCACA FV GCCAATCGCGACCTGACACGTC CCATACTGTGGACGTCACACAGAAGATT CD14 Fv gGTCGgAAQGCAGCTACTCCACAGT FV AATCTGTGCAGACGAGCAGTACT CC14 Fv gGTCGGAAGACGAGACAGTTC 109 ENSG0000162575 FV CCCATAGTGGAACGTCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGTGCACACAGAGAG FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGA FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCCGGCCGACACAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCATGGCCACACAGAGAGAG FV TGCCATCGCGC	Housekeeping gene			
B2M FW CGAQCAGGCCGTTCA FW CGAQGACGCCGCTTGA 100 ENSG0000160255 ENSG0000160255 Ceteogenesis FW FW CGAQAAgGCCAQACAGAAGCT 156 ENSG0000124813 ENSG0000124813 ENSG0000124813 RV AggATGCGCCTAAATCACT 190 ENSG0000124813 ENSG0000120821 ENSG0000124813 ENSG0000120821 Collagen I FW TCCAACGAGACTGACAGCT 190 ENSG0000120821 Osteonectin FW TACATCgg0CCTTGCAAATAC 100 ENSG0000120651 Collagenesis FW CCTGgACCAGTGTACCTTCT 67 ENSG0000120659 FANK FW CCTGQGCATCGTGTCTTGT 60 ENSG0000120659 FANK FW CACCCCCTGTTCCT FW QCCCAACCTGGTTCCTTGT FW QCCCAACCCGGATCATg FN GAGGTGATGGGTGTCCATA OPG FW CCGACGTGGTGGAGTAC FW QCCGACCCGGATCATg FN GAGGTGTGGAGTAC FW CGAGGTGGAGGGTACCT DC-STAMP FW ACAGCTGAGTGAGAGTTCT 100 ENSG0000164935 THAdP FW ACAGTGTGAGAGTACCTGGAGTACCT FW GAGGTGAGTGAGAGAGTAC FW GAGGTGAGTGAGAGAGTAC CD14 FW agGTAGGACAGAGCAGTACCTG 101 ENSG0000170458 RV TACTCGTGCCGATA FW GAGTGGAGGAGAGCAGAGCAGTAC FW GAGTGGAGGAGAGGAGCGAGCTACCT FW GAGTGGGAGGGAGCGAGCAGAGTAC FW GAGCGAACCTGGAGCAGAGCAGAGTACCT <td rowspan="2">HPRT</td> <td>Fw TgACCTTgATTTATTTgCATACC</td> <td>101</td> <td>ENSG00000165704</td>	HPRT	Fw TgACCTTgATTTATTTgCATACC	101	ENSG00000165704
B2M Fw CgACggCGCgTgTCA 100 ENSG00000160255 Cateogenesis Fw CCAgAAggCACAgACAgAAgCT 156 ENSG0000124813 RUNX2 Fw CCAgAAggCACAgACAgAAGCA 190 ENSG00000124813 Rv AggAATgCGCCAAATCACT 190 ENSG00000124813 Rv AggCAgATCCTagCAAATAC 100 ENSG00000108821 Osteonectin Fw TCAACGgAgACGTGTGT 67 ENSG00000231061 Rv AggCGAATTCCTgTGT 60 ENSG00000141655 RANK Fw CCTgACCAGTGTGTTCTCTGT 60 ENSG00000164761 Ordeocastogenesis Fw CCTgACCAGTCATGTTCCTGT 60 ENSG00000164761 Rv ACCGCAACCGTGTGTTCTCTGT 60 ENSG00000164761 OPG Fw CGTgCCAACCGTGTGTTCTCGT 8v AcCAGCGAATCATGTACAGTTCCTGTGT 100 ENSG00000164761 OFS Fw CCAGACCGAGTCATG 100 ENSG00000164761 OFG Fw CCAGAACCGTGAGTTCCGT 101 ENSG00000164935 TRACP Fw CCCAATCCTgCAGTACTGCAGAAGGTTCC 101 ENSG00000164935 Rv TGATCTGCAGTACTGCAGAGAGGTTCC 109 ENSG00000164935 Rv TGCCAAACCGGAGCTAACCTGCAGAGGAGTT 109 ENSG00000102575 Rv		Rv CGAgCAAgACgTTCAgTCCT		
Pkv TgTTgTTTTCAgCCAgCTTgTg Osteogenesis PUNX2 Fvv CCAgAAggCACAgACAgAACAgAAGCT 156 ENSG0000124813 RV AggCATGCGAgATCCC 190 ENSG0000108821 RV AggCagATTCGTgGTCT 100 ENSG0000108821 Octeonectin Fvv TACATCgggCCTTgCAAATAC 100 ENSG0000141655 PANK Fvv CCTggACCAAGTTGTGCCTCT 67 ENSG0000141655 RANK4 Fvv CCGgACTGTGTACCTTCCT 60 ENSG0000164761 RV AGCGAATTCTTgTTCTGTT 60 ENSG00000164761 GPG Fvv CGCGATCGTGTTTCTGT 60 ENSG00000164761 GPG Fvv GCGGATGTGTGTCCATAA 100 ENSG00000164761 GPG Fvv GCGGAGTGTGTGCCATAA 100 ENSG00000164761 GPG Fvv GCGGAGGTGTGCCAT 101 ENSG00000164761 CASTAMP Fvv ACAGCTGAGAGGTTCTCGAT 101 ENSG00000164761 CD14 Fvv GCGAAGGAGGTTCCGAT 128 ENSG00000164765 RV GCCAACGGAGGTTACCGAGAGGTTCC 103 ENSG00000170458 RV TCACTGGCGCAGAAGAGT 109 ENSG00000170458 RV TGCCGATAGGAGGTTACCGAGGAGGTT 100 ENSG00000170458	B2M	Fw CgACggCCgCTgTCA	100	ENSG00000160255
Osteogenesis FW CCAgAAggCACAgACAgAAgCT 156 ENSG0000124813 FUNX2 FW AggAATgCGCCTAAATCACT 190 ENSG0000124813 Collagen I FW TCCAACGAgATCCTgTGCT 190 ENSG0000108821 RV AAgCGGATTCTGTgTC 100 ENSG0000231061 Osteonectin FW TACATCgggCTTgCAAATAC 100 ENSG0000231061 Costeonectin FW ACAGTGgACCACTGTACCTTCCT 60 ENSG0000141655 RANK FW CCTggACCAACTGTACCTTCCT 60 ENSG0000120659 RANK FW CCCGACCCQATCATG 100 ENSG0000141655 RANKL FW CCCGACCCQATCATG 60 ENSG0000140659 RANKL FW CCCGACCCQATCATG 100 ENSG0000140659 CoPG FW CTGGCGCGCTGTGTTTC 60 ENSG0000144761 OPG FW CGCGACCCCQATCATG 100 ENSG0000164761 OFS FW CGCAACCCGATCGTGTTTC 100 ENSG0000164761 DC-STAMP FW CGCAACTGGAGTCCCAT 101 ENSG0000164935 RV gAATCATggAdGAAGCATGAGCAGTT 109 ENSG0000164935 RV GCAGTGTGCAT 109 ENSG0000102575 RV GCATACTGTGCAGCAACTGTGCACAAGGT 109 ENSG0000170458 RV TCATCGTGCAGCAAGCAGTTATC 143 ENSG00000170458 RV TCATCGTGCAAGAGAGAGTATC		Rv TgTTgTTTTCAgCCAgCTTgTg		
FW CCAgAAggCACAgAAGACT 156 ENSG0000124813 RV AggATIGCGCCTAAATCACT FW CCAGAGAGGAATCGAGATCC 190 ENSG0000108821 Collagen I FW TCCAAGGAGATCGAGATCC 190 ENSG0000126812 Osteonectin FW TACATCgAgGTCTGCAAATAC 100 ENSG0000126161 Osteonectin FW TACATCgagGCTTGCAAATAC 100 ENSG0000126161 RANK FW CCTgGACCAACTGTACCTTCCT 67 ENSG0000120659 RANK FW CCTGGACCACCGTGTACCTTCCT 60 ENSG0000120659 RANKL FW CATCCCATCTGTGTCCCATAA FW AGCGCAACCGGATCATGT 60 ENSG0000184371 OPG FW CTGGQGCGTGTGTTCTT 100 ENSG0000164761 00 ENSG0000164761 OPG FW CCGACAGGAGTTCGTGT 101 ENSG0000164761 00 ENSG0000164761 OPG FW CCGACAGTGAGTAGAGAGTTCC 101 ENSG00000164761 00 ENSG0000164761 OPG FW CCGAGGTGGTGTGTT 101 ENSG0000164761 00 ENSG0000164761 OPG FW CCGAGGTGTGAGTACCTCC T T ENSG0000164761 00 ENSG0000164761 OFG FW CCGAGTGTGAGAGACAGGTTCC 101	Osteogenesis			
Fv AggATgCgCCTAAATCACT 90 ENSG000010821 Collagen I Fw TCCAACQAQATCGAQATCC 190 ENSG0000010821 Osteonectin Fw TACATCgggCCTTgCAAATAC 100 ENSG0000231061 Deteoclastogenesis Fw CACGQAACGTGACCAGTGACCTTCCT 67 ENSG00001120659 RANK Fw CATCGCACTGTGGTCCACTAC 00 ENSG0000162616 RANKL Fw CATCGCACTGTGGTCCCATAA 00 ENSG0000162656 RANKL Fw CATCGCACTGTGGTTCCCATAA 00 ENSG0000164761 OPG Fw CATCGCACTGTGTGTTCTCTGT 00 ENSG0000164761 OPG Fw CGQAGGAGTGTGAGAGTTCTCGT 00 ENSG0000164761 OPG Fw CGQAggAggTGCGAGAGTTC 101 ENSG0000164761 OPG Fw CGGAGGAGAGTTCTCGATA 101 ENSG0000164761 DC-STAMP Fw CGAACCTGGAGTACCTGCAGAGTTC 101 ENSG0000164783 TRACP Fw CGCAATCTGGAGTCACCAGAGTTC 101 ENSG0000164783 CD14 Fw ggTCGgAAGCTTACCGACAAGGTTC 109 ENSG00001102575 Rv TCATCGTGCAGCTACAAGGAGTTC 109 ENSG00001170458 Rv TCATCGTGCAGCTACAAGGAGACTATCGACACAAGGAGACTAT FW AGCGAAGGTACAGAGAGAGTAT	RUNX2	Fw CCAgAAggCACAgACAgAAgCT	156	ENSG00000124813
Collagen IFw TCCAACgagATCGAgATCC190ENSG00000108821RV AAgCGgATTCCTggTCT100ENSG0000231061RV AdggTgACCAggACgTTCTTg67ENSG0000231061Osteoclastogenesis67ENSG00000141655RANKFw CCTgGACAACTGTACCTTCGT60ENSG00000120659RANKLFw CATCCACTGTgTCCCATAA70ENSG00000164761OPGFw CATCCACTGTgTTCTGT100ENSG00000164761OPGFw CACGCGATCATG70ENSG00000164761OPGFw CAGCGGATCATG70ENSG00000164761M-CSFFw CAGGCGATCATG70ENSG00000164761DC-STAMPFw AATTGGCAGAGGTTCCAT100ENSG00000164761TRACPFw CACAATCTGGAGATCCAT101ENSG00000164763FW CACATCTGCAGTATCCAT101ENSG00000164755RV GAATCATgGAAGACTTATCAGCAGAGTTTCC101ENSG00000102575TRACPFw CACAATCTGCAGAGGTATCCAT109ENSG00000102575RV CCATATGTGCAGAGGACTTATCAGACCAT109ENSG00000170458RV TGCATCATGTGCAGAGGTATC149ENSG00000143387CD14Fw GGTAGTTATCGACCAT100ENSG0000014387RV TGCATCATGTGCAGAGGTATC143ENSG00000131916RV TGCATCATGTGCACAAGG100ENSG0000013196FW TGCATCATGTGCCACACTCC100ENSG00000229899S' AgACAGGCACGAGCTAGAGATT 3'100ENSG0000229899S' AgACAGGCACGAGCTAT 3'100ENSG00002267684Cox1S' AgACAGGCACGAGCTAT 3'100ENSG00002267684Cox2S' GATTCTTTGCCCACACGAGCTT 3' <td>Rv AggAATgCgCCCTAAATCACT</td> <td></td> <td></td>		Rv AggAATgCgCCCTAAATCACT		
Fit AdgCcgAATTCCTggTCT Fit AdgCcggACTTgCAAATAC 100 ENSG0000231061 Bit AdgCggACTTGTGCAAATAC 100 ENSG00002141655 Osteoclastogenesis 67 ENSG0000141655 RANK Fw CCTggACCAACTGTACCTTCCT 60 ENSG000016659 RANKL Fw CATCGCATCTggTTCCCGTAA 700 ENSG0000164761 OPG Fw CATCGCACTCggTTTCTGT 100 ENSG00000164761 OPG Fw CGgCgGCTCTgTTTCGT 100 ENSG00000164761 OPG Fw CGgCgGQCTCGTGTTTCGT 100 ENSG00000164761 M-CSF Fw CGgAggAgTGTCGAACCAGT 100 ENSG00000164761 M-CSF Fw CATCGCAGTCGATTCTGGT 101 ENSG00000164761 M-CSF Fw CGAGAGTAGAGCAGATT 101 ENSG00000164761 M-CSF Fw CGAGAGTCGAGATA 100 ENSG00000164763 FW AGCTACGGAGACCGAGATA Fw GATCTCGCAGTCCGATTCGAGTCCT 103 ENSG00000102575 FW AGCGAGAGCAGACCTACCGCAAGGAGCATA 109 ENSG00000143837 FW CGACATCTGCCAGCGAGCCAAAGGAGTAT 143 ENSG00000143837 FW CGACATCTGCCAGCGAGCAAGAGAGTAT 143 ENSG00000143837 FW GGCAGAGCAAGGAGCAA	Collagen I	Fw TCCAACgAgATCgAgATCC	190	ENSG0000108821
Osteonectin Fw TACATCgggCCTTgCAAATAC 100 ENSG0000231061 r AvgggTgACCAggACgTTCTTg 67 ENSG0000211655 RANK Fw CCTggACCAACTgTACCTTCCT 60 ENSG0000120659 RANKL Fw CATCCATCggTTCCCATAA 7 ENSG0000164761 RV ACCCCQATCTGTGTTCCTGT 60 ENSG0000164761 RV GCCAACCCCQATCATg 100 ENSG0000164761 OPG Fw CTgCgCGCTGTGTTTCTCGT 100 ENSG0000164761 M-CSF Fw CGgAggAgTGTCGCAT 100 ENSG0000164761 DC-STAMP Fw AATTTGGCAGgAGTCCCAT 100 ENSG00000164935 TRACP Fw AATTTGGCAGgAGTCCTGCAT 101 ENSG00000164935 TRACP Fw CACAACTGTGAGCTGCAAGCAGATT 100 ENSG00000162575 RV CCCATAGTGGAACAAGCAGTTAC 101 ENSG00000102575 RV TGCTCGCCACCAACAGTGT 109 ENSG00000102575 RV TGCACATGTGGAGCAGAAGAAGTT 109 ENSG00000102575 RV TGCATGTCCAAGTGGAGCATTAC 100 ENSG00000143387 RV TGCATGTGCAAGGGAGCAAGAAGAGTT 149 ENSG00000143387 RV TGCATGTGTCCAATTGCACCTCC 100 ENSG00000131169 <td< td=""><td>Rv AAgCCgAATTCCTggTCT</td><td></td><td></td></td<>		Rv AAgCCgAATTCCTggTCT		
Pv AgggTgACCAggACgTTCTTg 67 ENSG00001141655 RANK Fw CCTgACCAACTGTACCTTCCTgT 60 ENSG0000120659 RANKL Fw CATCCCATCTggTTCCCATAA Ng GCCAACCCGgATCATg 100 ENSG0000164761 OPG Fw CTGCGCGGTGTTTC Ng ACCGACCTGgAGTTTCTCTgT 100 ENSG0000164761 M-CSF Fw CGGAggAggTTCTTGGT 100 ENSG0000164761 M-CSF Fw CGGAggAggTGTCGAGAGCACTT 100 ENSG0000164935 M-CSF Fw CGGAggAggTTCTCAGT 101 ENSG0000164935 M-CSF Fw CGCAACCCGAGAGAGCAGTTC 101 ENSG0000164935 RV AATTT3GCACGAGAGGTTC 101 ENSG0000164935 RV GACTGTGCAGTGCAGAGAGAT RV AATTT3GCACGAGAGATA ENSG00001102575 RV GACAATCTGCAGTGCAAGAGAT 128 ENSG00001102575 RV TCATCGTCCAACAAGGTATC 109 ENSG0000114387 RV TGATCAAT3GGCAACAAAGAGAGATAT 149 ENSG0000114387 RV TGATCGATGCCAACCT 143 ENSG0000131196 RV TGATCAAT3GGCACAAAGAGAGTTC 143 ENSG0000013196 RV gGTCAATTTGGCTCCATCC 143 ENSG0000013196 RV gGTCAATTTGGCCCAAGACGTTA' 100 <	Osteonectin	Fw TACATCgggCCTTgCAAATAC	100	ENSG0000231061
Octeodastogenesis67ENSG0000141655RANKFw CCTggACAACTGTACTTGTT60ENSG0000120659RANKLFw CATCCCATCTggTTCCCATAARv gCCCAACCCCGATCATG100ENSG0000164761OPGFw CTgCgCGCTCgTgTTCC100ENSG0000164761OPGFw CCGAAGCCGAAGAGAGGTTCCTGT100ENSG0000184371M-CSFFw CCgAggaggTGTCGgAGTACFw AATTTgCAACGAGgGTCCCAT101ENSG0000164365DC-STAMPFw AATTTgCAAGAGGAAGCAAGCAAGCATTC101ENSG0000164365TRACPFw CAAATCTgGAGTACCTGCAAGAGAGTTC128ENSG00001102575Rv GAATCATggAAGCAGCAAGCAAGAGAGTT128ENSG00001102575Rv CCCATAGTggAAGCAGACAAGAAGT109ENSG000001743887CD14Fw GCATATGTGGAGACGCAAT109ENSG00000143387Ntatc1Fw AGCAATCGTGCAAggAGTT143ENSG00000131196Rv gaGAGGCAGGAAGAFw agGCAGGTCACCAGAAGA100ENSG00000229899S' agAACTCCCTCGTTGT100ENSG00000229899Cox2S' agACCTCCCTGTT 3'100ENSG0000229899		Rv AgggTgACCAggACgTTCTTg		
RANK Fw CCTggACCAACTgTACCTTCCT Rv ACCgCATCggATTTCTCTgT 60 ENSG0000120659 RANKL Fw CATCCCATCggTTTCCCATAA Rv GCCAACCCgATCATg 100 ENSG0000164761 OPG Fw CTgCgCqCTCgTgTTTC Rv ACAgCTgATgAgAgAgTTCTTCgT 100 ENSG0000184371 M-CSF Fw ACAgCTgATgAgAgAgTTCTTCGT 100 ENSG0000164761 DC-STAMP Fw ATTTGGCACGAgGTCCCAT 101 ENSG00000164935 TRACP Fw ACATTGGAGAGCAGCAGTTC 101 ENSG00000164935 CD14 Fw gGTC3gAAGACTTATCGACCAT 128 ENSG00000170458 Rv TCATCGTCCAGCTCACAAggT 149 ENSG00000143371 Ntatc1 Fw AGAGAGCAGgAAGAGAGATAT 149 ENSG00000143387 Ntatc1 Fw AGAgGACGgAGAGCAGTATC 143 ENSG00000131196 Rv gGCAGTCCCTGATACGAGAGAGTTATC 143 ENSG00000131196 Rv gGCAGTCCCTGATGAGAGAGAGTTATC 100 ENSG00000229899 GC0x1 5' AgATACAGGTACGAGCAGTTACC 3' 100 ENSG00000229899 GC0x2 5' gCATTCTTGTGCCAGCCAAAGAG 3' 100 ENSG00000229898	Osteoclastogenesis		67	ENSG00000141655
Rv ACCgCATCggATTTCTCTgT60ENSG0000120659RANKLFw CATCCCATCTggTTCCCATAAENSG0000164761Rv gCCCAACCCgATCATg100ENSG0000164761OPGFw CTgCgCgCTCTGTTC100ENSG0000184371M-CSFFw CCgAggAggTGCggAgTAC Rv AATTGCACAgdgTCTCCAT100ENSG0000164936DC-STAMPFw ATTTGCCAgTgACAgAgCATTC Rv GACCAAGCGATACTGGATAATTCTTGAGTGACAAggAT128ENSG0000102575RtACPFw CCAAACTG1CCACTGCACAT Rv GCCAAGTG2CAAGGAGTAC109ENSG0000170458 Rv GCCAAGTG3CAAggATCD14Fw ggTCGgAAgACCTATCGACCAT Rv TCATCgTCCAGTCCCACAGgT149ENSG0000143387 RV TGCCAGTCACAAggATNtatc1Fw AGCAgAgCACggACAGgAAgAGTTATC Rv ggCCAGTACGTGCCACCATCC Rv ggCCAGTATCCGTCCCACAggAT143ENSG0000131196 RV ggCAGgCAGgACGCAGTATC RV GGCCAGGCATGCC 3'Cox25' AgTACAGCTAGQGCAGGTATC S' AgACCCAggCACCGAACCAAAgg 3'100ENSG0000226784 S' AgACCCAggCACCGAACCAAAgg 3'	RANK	Fw CCTggACCAACTgTACCTTCCT		
RANKLFw CATCCCATCTggTTCCCATAA100ENSG0000164761PGRv gCCCAACCCgATCATg100ENSG0000164761OPGRv CTgCgCgCTCgTgTTTC100ENSG0000184371M-CSFFw CCgAggAggTTCggAgTACRv AATTTggCACgAggTTCCCAT101ENSG0000164935DC-STAMPFw ATTTGCAGTGACAGCAGTTTC101ENSG0000164935Rv gATCATggATACATATCTTgAgTTCCTT128ENSG0000102575TRACPFw cCAAATCTGCAGTACCTGCAAggAT128ENSG0000170458Rv CCCATAGTGGAAgCGAGTAC109ENSG0000170458Rv TCATCGTCGCAGTCACCAAggT143ENSG000014337CD14Fw gGTTCggAAgCAggAgAgAgAgT143ENSG000014337Rv TCATCGTCGCAGCTCACAAggT143ENSG00001131196Rv gGCAGAGCGACAGAGCATC143ENSG00000131196Rv gGTCAGTTCCGATCCC100ENSG00000229899Sr gAgACTCCTgGCAGCAGACTT 3'100ENSG00000229899Sr gAgACTCCTGGCAGCAGACCT 3'100ENSG00000267084Sr AgACCAggCACCAGACCAGACT 3'100ENSG00000267084Sr AgACCAGGCACCAGACCTT 3'100ENSG0000267084Sr AgACCAGGCACCAGACCATT 3'100ENSG0000267084Sr AgACCAGGCACCAGACCTT 3'100ENSG0000267084Sr AgACCAGGCACCAGACCAAAGA 3'SrSrSr AgACCAGGCACCAGACCATAGASrSrSr AgACCAGGCACCAGACCAAAGA 3'SrSrSr AgACCAGGCACCAGACCAAAGA 3'SrSrSr AgACCAGGCACCAGACCAAAGA 3'SrSrSr AgACCAGGCACCAGACCAAAGA 3'SrSrSr AgACCAGGCACCAGACC		Rv ACCgCATCggATTTCTCTgT	60	ENSG00000120659
Rv gCCCAACCCCgATCATg100ENSG0000164761OPGFw CTgCgCgCTCTgTTTC Fw CACACTGgATgAGAgTTTCTCgT100ENSG0000184371M-CSFFw CCgAggAggTgTCgGAgTAC Fw ATTTgCACGAggGTCCCAT101ENSG0000164935 ENSG0000164935 Rv gAATCATgGAAgCAgTTCC101ENSG0000164935 ENSG0000164935 Rv gAATCATgGATAATATCTTgAgTCCTTTRACPFw ATTTTCCAgTgAgCAAgCAgTTC101ENSG000012575 ENV CCCATAGTGGAAgGAGTA128ENSG0000102575 ENSG0000102575 RV CCCATAGTGGAAGGAGTACD14Fw gGTCGgAGAGCAGCAGCAGACAA Rv TCATCgTCCAagGACCTATCGAGGAGAA149ENSG0000143387 ENSG0000143387Nfatc1Fw CACAATGTgGAAGAGAgAGAGTAT149ENSG0000131196 Rv gGTCAGTTTCGCATCTCCox15' AgTACAGCTAGCAGAGGAGTAT'100ENSG00000229899 5' gAgACTCCCTgATGCACAAAgA 3'	RANKL	Fw CATCCCATCTggTTCCCATAA		
OPGFw CTgCgCgCTCgTgTTTC Rv ACAgCTgATgAgAggTTCTTCgT100ENSG0000184371M-CSFFw CCgAggAggTgTCggAgTAC Rv AATTTgCAAgTagAAgCAgTTCCAT101ENSG00000164935DC-STAMPFw ATTTTCTCAgTgAgCAAgCAgTTCC Rv gATCATggATAATATCTTgAgTTCCTT101ENSG00000164935TRACPFw GACAATCTgCAAgTAGCCTgCAAggAT128ENSG00000102575Rv CCCATAGTggAAgCGCAGATAA109ENSG00000170458Rv TCATCgTCCAgCCACAAggT149ENSG00000170458Rv TCATCgTCCAgCCACAAggAT149ENSG00000143387Rv TGATCGTCCAGCCACAAggAT143ENSG00000131196Rv TGATCATTgCgCACAGAGAA100ENSG00000131196Rv TgCATCATCgCCACAGAGTTG'100ENSG00000229899S Cox1S' AgTACAAgCAGCAGCAGCTT 3'100ENSG00000229899S Cox2S' GCATTCTTTGCCCAgCCACT 3'100ENSG00000229893Cox2S' GCATTCTTTGCCCAgCCACAAGA 3'100ENSG00000267084		Rv gCCCAACCCCgATCATg	100	ENSG00000164761
Rv ACAgCTgATgAgAggTTTCTTCgT100ENSG0000184371M-CSFFw CCgAggAggTGTCgAgTAC Rv ATTTTgQCCCAgTGTCCCATFw CCGAggAggTCTCCATENSG0000164935DC-STAMPFw ATTTTCCAgTgAgCAAgCAGTTCTTgAGTTCCTT101ENSG0000164935TRACPFw CACAATCTGCAGTAACCTGCAAggAT128ENSG00000102575Rv CCATATGTGGAAgCAGCAGTAAC109ENSG00000170458Rv TCATCgTCCAgCTCACAAggAT149ENSG00000143387CD14Fw ggTTCggAAgACTTATCgACCAT109ENSG00000143387Rv TCATCgTCCAgCTCACAAggT143ENSG00000131196Rv TGATCATGgTGGAGAGACAGTATC143ENSG00000131196Rv gGCAGTTACCGAGCAGTAC100ENSG0000022989Ocx15' AgTACAgCTAGQACACTT 3'100ENSG0000022989Cox25' gCATTCTTTgCCCAgCACTT 3'100ENSG0000022984Fw AgCAggCACggACACTTATCGTC100ENSG000022984Fw AgCAggCACGgACACTT 3'100ENSG000022984Fw AgCAggCACCGAGCACTT 3'100ENSG0000267084Fv AgCAggCACCGAGCACTT 3'100ENSG0000267084Fv AgCAggCACCGAGCCACAAAgA 3'Fv AgCCAggCACCAAAGA 3'Fv AgCCAggCACCAAAGA 3'	OPG	Fw CTgCgCgCTCgTgTTTC		
M-CSF Fw CCgAggAggTgTCggAgTAC Rv AATTTggCACgAggTCTCCAT 101 ENSG0000164935 DC-STAMP Fw ATTTTCTCAgTgAgCAAgCAgTTC 101 ENSG0000164935 Rv gATCATggATAATATCTTgAgTTCCTT 128 ENSG0000102575 TRACP Fw CACAATCTgCAgTACCTgCAAggAT 128 ENSG0000170458 Rv CCCATAGTggAAgCGCAgGTA 109 ENSG0000170458 Rv TCATCgTCCAgCTCACAAggT 149 ENSG0000143387 Cathepsin K Fw CCATATgTgggACAggAAgAgAgTT 149 ENSG0000131196 Nfatc1 Fw AgCAggCACggACAgCTATC 143 ENSG0000131196 Nfatc1 Fw AgCAggCACggACAgTT 3' 100 ENSG0000229899 S' AgTACAgCTACgAgCATT 3' 100 ENSG0000229899 S' agACTCCCTgATgAGCACCA3AGX 100 ENSG0000229899		Rv ACAgCTgATgAgAggTTTCTTCgT	100	ENSG00000184371
Rv AATTTggCACgAggTCTCCAT101ENSG0000164935DC-STAMPFw ATTTTCTCAgTgAgCAAgCAgTTC101ENSG0000102975Rv gAATCATggATAATATCTTgAgTTCCTT128ENSG0000102575TRACPFw CACAATCTgCAgTACCTgCAAggAT109ENSG0000170458Rv CCATAGTggAAgCGCAAggT109ENSG00001143387CD14Fw ggTCggAAgACTTATCgACCAT109ENSG00000143387Rv TCATCgTCCAQGTCACAAggT149ENSG00001143387Rv TGATCAATggCCACAGgAAgAGTT143ENSG0000131196Rv TgCATCAATggCCACAGgACAGTTATC143ENSG0000131196Cox15' AgTACATCGQCCACGAGAGT100ENSG0000229899S' gQACTCCCTgATgACATCC 3'100ENSG0000229899Cox25' gCATTCTTTgCCCAgCACTA 3'100ENSG0000229893S' AgACCAggCACCAGAAGCAT 3'100ENSG0000229893S' AgACCAGGCACAAGACTT 3'100ENSG0000229893S' AgACCAGGCACAGACTA 3'100ENSG0000267084S' AgACCAggCACCAAAGA 3'5' AgACCAggCACCAAAGA 3'100	M-CSF	Fw CCgAggAggTgTCggAgTAC		
DC-STAMPFw ATTTTCTCAgTgAgCAAgCAgTTTC101ENSG0000164935Rv gAATCATggATAATATCTTgAgTTCCTT128ENSG0000102575TRACPFw CACAATCTgCAgTACCTgCAAggAT128ENSG0000102575Rv CCCATAGTggAAgCgCAgATA109ENSG0000170458CD14Fw ggTCggAAgACTTATCgACCAT109ENSG0000143387Rv TCATCgTCCAgCTCACAAggT149ENSG00000143387Cathepsin KFw CCATATgTgggACaggAAggAgTT149ENSG0000131196Nfatc1Fw AgCAgAgCACggACAggACgTCCTCCACAGAgAG143ENSG0000131196V fact01Fv AgCAgGCACggACAgCAGTT 3'100ENSG00000229899S' gAgACTCCCTgATgACATCC 3'5' gCATTCTTTgCCCAgCACTA 3'100ENSG00000229899Cox2S' gCATTCTTTgCCCAgCACTA 3'100ENSG00000227084S' AgACCAggAACCAGAACTCC 3'100ENSG00000267084S' AgACCAggCACCAgACCAAAgA 3'100ENSG00000267084		Rv AATTTggCACgAggTCTCCAT		
Rv gAATCATggATAATATCTTgAgTTCCTT TRACP Fw CACAATCTgCAgTACCTgCAAggAT 128 ENSG00000102575 Rv CCCATAGTggAAgCGCAgATA 109 ENSG00000170458 CD14 Fw ggTTCggAAgACTTATCgACCAT 109 ENSG00000143387 Rv TCATCgTCCAgCTCACAAggT 149 ENSG00000143387 Cathepsin K Fw CCATATgTgggACagGAAgAAgAgTT 143 ENSG00000131196 Nfatc1 Fw AgCAgGACGgACAggACagTT 3' 143 ENSG00000131196 Cox1 5' AgTACATgCAgAgCAGgACTT 143 ENSG00000229899 5' ggAACTCCCTgATgACATCC 3' 100 ENSG00000229899 Cox2 5' gCATTCTTTGCCCAgCACAAgA 3' 100 ENSG0000227604	DC-STAMP	Fw ATTITCTCAgTgAgCAAgCAgTTTC	101	ENSG00000164935
TRACPFw CACAATCTgCAgTACCTgCAAggAT128ENSG0000102575Rv CCCATAGTggAAgCgCAgATA109ENSG0000170458CD14Fw ggTTCggAAgACTTATCgACCAT109ENSG0000170458Rv TCATCgTCCAgCTCACAAggT149ENSG0000143387Cathepsin KFw CCATATgTgggACaggAAgAgAgTT149ENSG0000131196Rv TgCATCAATggCCACAgAgA143ENSG0000131196Nfatc1Fw AgCAgAgCACggACAggCAGTT 3'100ENSG00002298995' gAgACTCCTgATgACATCC 3'5' gCATTCTTTgCCCAgCACTT 3'100ENSG0000220849Cox25' gCATTCTTTgCCCAgCACTA 3'100ENSG0000267084		Rv gAATCATggATAATATCTTgAgTTCCTT		
Rv CCCATAGTggAAgCgCAgATA 109 ENSG0000170458 CD14 Fw ggTCggAAgACTTATCgACCAT 109 ENSG0000170458 Rv TCATCgTCCAgCTCACAAggT 149 ENSG0000143387 Cathepsin K Fw CCATATgTgggACAggAAgAgAgAgTT 149 ENSG0000143387 Rv TgCATCAATggCCACAgAgA Rv TgCATCAATggCCACAgAgA 143 ENSG0000131196 Rv ggTCAgTTTCgCTTCCATCTC 143 ENSG00000229899 5' gAgACTCCCTgATgACATCC 3' 100 ENSG0000229899 Cox2 5' gCATTCTTTgCCCAgCACTT 3' 100 ENSG00002267084 5' AgACCAggCACCAAAGA 3'	TRACP	Fw CACAATCTgCAgTACCTgCAAggAT	128	ENSG00000102575
CD14Fw ggTtCggAAgACTTATCgACCAT109ENSG0000170458 RV TCATCgTCCAgCTCACAAggTCathepsin KFw CCATATgTgggACAggAAgAgAgTT149ENSG0000143387 RV TgCATCAATggCCACAgAgANfatc1Fw AgCAgAgCACggACAgCTATC143ENSG0000131196 RV ggTCAgTTTCgCTTCCATCTCCox15' AgTACAgCTACgAgCAGTT 3'100ENSG0000229899 5' gAgACTCCCTgATgACATCC 3'Cox25' gCATTCTTTgCCCAgCAGTT 3'100ENSG00002267084 5' AgACCAggCACCgACCAAgAG 3'		Rv CCCATAGTggAAgCgCAgATA		
Rv TCATCgTCCAgCTCACAAggT 149 ENSG0000143387 Cathepsin K Fw CCATATgTgggACAggAAgAgAgTT 149 ENSG0000143387 Rv TgCATCAATggCCACAgAgA Fw AgCAgAgCACggACAgCTATC 143 ENSG0000131196 Rv ggTCAgTTTCcgCTCCATCTC 143 ENSG0000229899 S' AgTACAgCTACgAGCAGTT 3' 100 ENSG0000229899 S' gAgACTCCCTgATgACATCC 3' 100 ENSG0000267084 Cox2 S' gCATTCTTTgCCCAgCACTT 3' 100 ENSG0000267084	CD14	Fw ggTTCggAAgACTTATCgACCAT	109	ENSG00000170458
Cathepsin KFw CCATATgTgggACAggAAgAAgAAgTT149ENSG0000143387Rv TgCATCAATggCCACAgAgARv TgCATCAATggCCACAgAgA143ENSG0000131196Nfatc1Fw AgCAgAgCACggACAgCTATC143ENSG00000131196Rv ggTCAgTTTTCgCTTCCATCTC5' AgTACAgCTACgAgCAgTT 3'100ENSG000002298995' gAgACTCCCTgATgACATCC 3'5' gCATTCTTTgCCCAgCAGTT 3'100ENSG0000220899Cox25' gCATTCTTTgCCCAgCACTT 3'100ENSG00002670845' AgACCAggCACCAgACCAAgAC 3'5' AgACCAggCACCAAgAC 3'Find the section of the section o		Rv TCATCgTCCAgCTCACAAggT		
Rv TgCATCAATggCCACAgAgA Nfatc1 Fw AgCAgAgCACggACAgCTATC 143 ENSG0000131196 Rv ggTCAgTTTCgCTTCCATCTC 100 ENSG0000229899 5' AgTACAgCTACGAGCAGCTATC 3' 100 ENSG0000229899 5' gAgACTCCCTgATgACATCC 3' 100 ENSG0000267084 Cox2 5' gCATTCTTTgCCCAgCAGTT 3' 100 ENSG0000267084	Cathepsin K	Fw CCATATgTgggACAggAAgAgAgTT	149	ENSG00000143387
Nfatc1Fw AgCAgAgCACggACAgCTATC143ENSG0000131196Rv ggTCAgTTTCgCTTCCATCTCRv ggTCAgTTTCgCTTCCATCTC100ENSG00002298995' gAgACTCCCTgATgACATCC 3'100ENSG0000229899Cox25' gCATTCTTTgCCCAgCACTT 3'100ENSG00002670845' AgACCAggCACCAgACCAAgA 3'5' AgACCAggCACCAagAC 3'ENSG0000267084		Rv TgCATCAATggCCACAgAgA		
Rv ggTCAgTTTCgCTTCCATCTC Cox1 5' AgTACAgCTACgAgCAgTT 3' 100 ENSG0000229899 5' gAgACTCCCTgATgACATCC 3' 5' gCATTCTTTgCCCAgCACTT 3' 100 ENSG0000267084 Cox2 5' gCATTCTTTgCCCAgCACAAgA 3' 100 ENSG0000267084	Nfatc1	Fw AgCAgAgCACggACAgCTATC	143	ENSG00000131196
Cox1 5' AgTACAgCTACgAgCAgTT 3' 100 ENSG0000229899 5' gAgACTCCCTgATgACATCC 3' 5' gAgACTCCCTgATgACATCC 3' ENSG0000229899 Cox2 5' gCATTCTTTgCCCAgCACTT 3' 100 ENSG0000229899 5' AgACCAggCACCAgACCAAgA 3' 5' AgACCAggCACCAAgAC 3' ENSG0000267084		Rv ggTCAgTTTTCgCTTCCATCTC		
5' gAgACTCCCTgATgACATCC 3' Cox2 5' gCATTCTTTgCCCAgCACTT 3' 100 ENSG0000267084 5' AgACCAggCACCAAgAC 3'	Cox1	5' AgTACAgCTACgAgCAgTT 3'	100	ENSG00000229899
Cox2 5' gCATTCTTTgCCCAgCACTT 3' 100 ENSG0000267084 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' AgACCAggCACCAAgAC 3' 5' 5' AgACCAggCACCAAgAC 3' 5' 5' AgACCAggCACCAAgAC 3' 5'		5' gAgACTCCCTgATgACATCC 3'		
5' AgACCAggCACCAAgA 3'	Cox2	5' gCATTCTTTgCCCAgCACTT 3'	100	ENSG00000267084
		5' AgACCAggCACCAgACCAAAgA 3'		

manufacturer's instructions. The cells were counterstained with DAPI (diamidino-2phenylindole dihydrochloride). A distinction was made between cells with 3-5 nuclei, and cells with ≤ 6 nuclei. For analyses, the average of the number counted in the duplicate wells per patient was used.

Blood Cell Isolation

Buffy coats (Sanquin, Amsterdam, Netherlands) of healthy donors were diluted 1:1 in 1% PBS-citrate (pH 7.4). Thereafter, 25 ml of diluted blood was carefully layered on 15 ml Lymphoprep (Axisshield Po CAS, Oslo, Norway) and centrifuged for 30 min at 800 x G without brake. The interphase containing the PBMCs was collected and washed three times in 1% PBS-citrate by spinning down the cells at 400 g with full brakes and by decanting the supernatant. Finally, the cells were recovered in culture medium.

Monocyte Isolation

CD14⁺ monocytes retrieved from peripheral blood were used in experiments where osteoclasts were grown using M-CSF and RANKL instead of fibroblasts and PBMCs. Here, CD14⁺ cells were isolated using CD14⁺ microbeads (Miltenyi, Bergisch Gladbach, Germany) according to a previously described method (Ten Harkel et al., 2015). CD14⁺ monocytes were cultured for 3 days in M-CSF (25 ng/ml), followed by 10 ng/mL M-CSF and 10 ng/ml RANKL until 21 days.

Bone Resorption

Bone resorption was analyzed in cultures on bone after a culture period of 21 days. After this period, the cells present on the bovine cortical bone slices were removed with 0.25 M NH_4OH followed by sonication in ice water for 30 min. The slices were washed in distilled water, incubated in a saturated alum solution, washed in distilled water, and stained with Coomassie Brilliant blue. The surface areas of individual resorption pits were measured using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD).

Statistical Analysis

The effects on the cells between different metformin concentrations over time were compared using one way ANOVA followed by the non-parametric Friedman test, using GraphPad Prism software. Dunn's multiple comparison test was done as a post-test. A *p* value of **p* ≤ 0.05 was chosen to determine the level of significance.



RESULTS

Metformin Titration in Periodontal Ligament Mediated Osteogenesis

In order to establish whether metformin plays a role in periodontal ligament driven osteogenesis, we added 5-fold dilutions (0.008–1 mM) of metformin in mineralization assays (n = 3 donors). As first measurement, we assessed whether metformin could influence proliferation, measure of how metformin could influence metabolic activity such as proliferation. Metformin had no effect on proliferation (**Supplementary Figure S1A**), nor on the alkaline phosphatase activity per cell (**Supplementary Figure S1B**). Alizarin red staining showed donor variability at 14 days, which vanished at 21 days (**Supplementary Figure S1C**). At higher magnification, the alizarin red staining appeared in nodule-like structures (**Supplementary Figure S1D**). No clear effect of metformin on mineralization was observed.

Metformin Does Not Affect Periodontal Ligament Mediated Osteogenesis

The above titration experiment showed that metformin was tolerated at high concentrations and seemed not to affect osteogenesis. All subsequent osteogenesis and osteoclastogenesis experiments were performed using a higher number periodontal ligament donors (n = 6) with 0.2 and 1.0 mM metformin. Compared to day 0, ALP enzyme was significantly higher at day 14, with no differences between normal medium, mineralization medium without or with metformin (Figure 2A). Alizarin red staining demonstrated greater variability compared to the donors of Figure 1, but again with no clear metformin effect (Figure 2B). qPCRs for early osteogenic marker RUNX 2 (Figure 2C), Collagen type I (Figure 2D) and late osteogenic marker Osteonectin (Figure 2E) showed an increase in expression over time (t = 0 vs. t = 14) for all genes. Only osteonectin expression differed between normal medium and mineralization medium at t = 14 days. Metformin had no effect on osteogenic gene expression. These experiments together showed that metformin did not affect osteogenic differentiation of periodontal ligament fibroblasts.

Effect of Metformin in Periodontal Ligament- PBMC Co Cultures

As previously shown (De Vries et al., 2017; Ruppeka-Rupeika et al., 2018; Loo-Kirana R.; Gilijamse M.; Hogervorst J., 2021), the periodontal ligament plays a role in both osteogenesis and osteoclastogenesis. We next assessed whether metformin could



inhibit osteoclast formation by making use of periodontal ligament fibroblasts-PBMC co-cultures. To determine the number of osteoclasts, cells were stained with TRAcPand counterstained with DAPI to visualize nuclei. Cells containing ≥ 3 nuclei are considered as osteoclasts. Metformin was used in concentrations that did not affect osteogenesis: 0.2 and 1.0 mM. A decrease in osteoclast formation was observed with both concentrations (Figures 3A-C), affecting total number of cells containing more than two nuclei (Figure 3D), the smaller ones containing 3-5 nuclei (Figure 3E) as well as the larger ones with six and more nuclei (Figure 3F). Expression of genes associated with osteoclast formation such as RANKL (Figure 3G), OPG (Figure 3H), M-CSF (Figure 3J), and osteoclast genes TRACP (Figure 3K) and DC-STAMP (Figure 3L) displayed a similar pattern of decreased expression in the presence of 0.2 or 1.0 mM metformin. RANKL was not detetable by qPCR in monocyte cultures stimulated with M-CSF and RANKL. OPG was detected with high Ct values, with an unreliable relative expression between 0.0002 and 0.001. These results confirm what we have previously seen (De Vries et al., 2006; Bloemen et al., 2010), showing that OPG and RANKL were solely expressed by periodontal ligament fibroblasts in co culture. Monocyte marker CD14 was elevated at 0.2 mM of metformin (Figure 3M), suggesting that the inhibitory effect of metformin was due to a decrease in osteoclast differentiation rather than loss of precursor cells.

Metformin Inhibits M-CSF and RANKL Mediated Osteoclast Formation and Bone Resorption

Although periodontal ligament fibroblasts contribute to osteoclast formation, M-CSF and RANKL are required for the generation of bone resorbing osteoclasts (De Vries et al., 2006). In order to study the effect of metformin on M-CSF and RANKL mediated osteoclast formation and bone resorption, CD14⁺ cells were seeded on plastic or bone for assessing the impact of metformin on osteoclastogenesis. In a separate seeding on bone, the effect on bone resorption was assessed.

As in the co-cultures, metformin inhibited osteoclast formation in a dose dependent manner on plastic (**Figures 4A–C**) as well as on bone (**Figures 4D–F**). Note that monocytes remained mononuclear at 1.0 mM metformin (**Figures 4B,E**). In parallel to decreased osteoclast formation on bone slices, bone resorption was abolished at 1.0 mM metformin (**Figure 4H**).

Gene expression of osteoclast genes RANK and CathK was inhibited at high dose of metformin (**Figure 5**). Peculiarly, the reverse was true for TRACP expression (**Figure 5**), where higher expression was observed when cultured with 1.0 mM metformin. Expression of DC-STAMP, Nfatc1 and CD14 was not altered by metformin.

Gene expression of mitochondrial markers COX1 and COX2 tended to be lower at 1.0 mM metformin (**Supplementary Figure S2** (non-significant).



FIGURE 3 | Metformin inhibits periodontal ligament fibroblasts mediated osteoclast formation. PBMC were cultured on periodontal ligament fibroblasts and osteoclast formation was assessed at 21 days after TRAcP staining (A–C). (A) Control, without metformin, (B) 0.2 mM metformin and (C) 1.0 mM metformin. (D–F): Inhibition of numbers of multinucleated cells (MNC) formed, both when assessing all multinucleated cells (D, >2 nuclei), small multinucleated cells with 3-5 nuclei (E), or larger multinucleated cells (F, 6+ nuclei). (G–M): Gene expression at 0 days (C, periodontal ligament fibroblasts without PBMCs) or 21 days (co-cultures periodontal ligament fibroblasts 0, 0.2 and 1.0 mM metformin) of RANKL (G), OPG (H), the ratio RANKL/OPG (I), M-CSF (J), TRACP (K), DC-STAMP (L), and CD14 (M) is inhibited by metformin. All results are from n = 6 periodontal ligament fibroblast donors. White arrow in A and B: multinucleated cells, Yellow arrow in C: fibroblast nucleus, Red arrow in C: PBMCs that are not fused and TRACP negative. # in G–I: Control significantly lower ($\rho < 0.05$) expression than 0 and 0.2 mM metformin in co-cultures. *: $\rho < 0.05$; **: $\rho < 0.05$. All data are from n = 6 donors. Osteoclast assay (A–F) was performed twice, obtaining similar results, with two groups of six different donors (by LT and KL), results from one experiment are shown.

DISCUSSION

Various animal (Bak et al., 2010; Araújo et al., 2017) and clinical studies (Pradeep et al., 2013; Pradeep et al., 2015; Pradeep et al., 2016; Pradeep et al., 2017; Kurian et al., 2018) have pointed out a beneficiary effect of metformin in down modulating the severity of periodontitis, when induced or when used as a clinical adjuvant

improving bone health and periodontal status. The present study contributes to an understanding at the cellular level using the appropriate model of periodontal ligament fibroblasts. Using two confirmatory assays, results unequivocally point out a role for metformin by inhibiting osteoclast formation and activity.

Our original hypothesis that metformin would have a positive effect on osteogenesis, has to be partially rejected and modified.





Based on our results, metformin treatment did not induce alkaline phosphatase activity nor did it increase Alizarin Red staining. This is in line with a recent publication on the effect of metformin on periodontal ligament fibroblasts (Jia et al., 2020). In contrast to Jia et al., we did not observe a positive effect on osteogenic markers such as RUNX-2. Differences in periodontal ligament fibroblast heterogeneity, such as seen for Alizarin Red staining in Figure 2B could account for this difference, but also methodological differences, such as use of dexamethasone and a different concentration of ascorbic acid and glycerophosphate could give rise to such discrepancies. Concentrations that were used in our study did not affect proliferation, since no differences in DNA content were observed in the titration experiment (Suppl. Figure 1A). As in previous studies from our group (Karlis et al., 2020; Loo-Kirana et al., 2021), the observed Alizarin Red staining was due to so-called nodules or hot-spots of mineralization that formed on top of the fibroblasts (Figure 1D). Interestingly, mineralization medium only induced osteopontin expression when compared to normal medium, whereas RUNX-2, Collagen-I expression and the activity of Alkaline phosphatase was not influenced, not by mineralization medium nor by metformin. Clearly, most of the expression data revealed a time effect (t = 0 vs. 14 days), which possibly can be explained by a more confluent layer of cells, whichmay ignite these expressions. By nature, periodontal ligament fibroblasts express alkaline phosphatase abundantly (Groeneveld et al., 1995), which may explain why mineralization medium did not alter the expression.



together with peripheral blood monochuclear cells (PBNCs) under continual exposure to methormin. The effect of methormin on osteoclast formation was further assessed with CD14⁺ monocytes that were subjected to osteoclast differentiation with osteoclastogenesis driving cytokines M-CSF and RANKL. Our results all indicate an inhibitory effect on osteoclast formation, which could, in a broader sense, be the mechanism that explains clinically observed bone improvement in metformin users.

Metformin inhibited osteoclast formation or osteoclastogenesis in the periodontal ligament-PBMC co cultures. Downregulation of typical osteoclastogenesis genes, such as RANKL and M-CSF, that are expressed by periodontal ligament fibroblasts as well as the downregulation of osteoclast gene DC-STAMP shows that metformin affects both the fibroblast side that orchestrate osteoclast formation (RANKL and M-CSF), as well as precursor cells (DC-STAMP). Downregulation of DC-STAMP most likely resulted in a lack of fusion (Figure 3C), where only mononuclear cells were seen in conjunction with fibroblasts. Concerning mechanistic insight, pleotropic effects of metformin beyond facilitating insulin's glucose lowering effects should be considered (Ursini et al., 2018). It has been described in a cell culture using gingiva fibroblasts that metformin reduces the expression of inflammatory factors IL-1β, TNF-α and IL-6 (Wu et al., 2015; Kang et al., 2017). Recently, we showed that co-cultures of gingiva fibroblasts with leukocytes induces IL-1 β and TNF- α (Moonen et al., 2018), but also periodontal ligament fibroblasts induce M-CSF, IL-1β and TNF-α early during osteoclast formation (Bloemen et al., 2010). These factors are adjuvant cytokines for osteoclast formation, since osteoclast formation can be inhibited by anti-TNF (De Vries et al., 2016; Zamri and De Vries, 2020) and stimulated by TNF- α (Cao et al., 2017) and IL-1 β (Cao et al., 2016). In vivo evidence for metformin anti-inflammatory mode of action was obtained in a mouse model of rheumatoid arthritis (Fan et al., 2020) where it primarily affected IL-1β. Together with the downregulated crucial osteoclastogenesis factor RANKL (Kong et al., 1999) (Figure 3G), it seems likely that also other inflammatory osteoclastogenesis genes could be affected. Downregulation of RANKL was also seen in

ovariectomized rats that were treated with metformin (Mai et al., 2011), who also showed that this brought down the number of osteoclasts *in vivo*. Co. cultures in the present study were performed with unsorted PBMCs, which makes it likely that also Th17 T-cells were present in the culture. These cells may contribute to osteoclast formation by interacting with osteoclast precursors (Moonen et al., 2018), producing the osteoclastogenesis activating cytokine IL-17 (Sprangers et al., 2016). Interestingly, it was shown that metformin lowers the Th17/Treg ratio (Son et al., 2014). Whether metformin affects this T-cell subset and thus contribute to the inhibitory effect remains to be investigated.

Metformin likewise inhibited monocytes in the absence of periodontal ligament fibroblasts to differentiate into osteoclasts, both on plastic and on bovine bone slices. Here, no resorptive activity was observed when the highest concentration of metformin was used. qPCR revealed cathepsin K and RANK to be downregulated by metformin, mRNAs that could not be identified as osteoclast precursor specific in the cocultures with periodontal ligament fibroblasts, since these molecules are also detectable in monocultures of periodontal ligament fibroblasts. These results indicate that metformin inhibits genes important for early differentiation events (RANK) as well as genes involved in differentiated osteoclasts, such as cathepsin K. One of the mechanistically interesting aspects that could explain the observed reduced osteoclast formation and function, is metformin's mildly inhibitory effect on mitochondrial function (Apostolova et al., 2020). Recent studies interfering with osteoclast presence (Weivoda et al., 2020) could correlate osteoclast activity to a general energetic state. Abundance of mitochondria is a hallmark of osteoclasts, and interference with

mitochondrial function interferes with osteoclast formation (Park-Min, 2019; Weivoda et al., 2020). Preliminary results indicate that 1.0 mM could have a downregulatory effect on the expression of mitochondrial markers COX1 and COX2 (Figure 5B). Contra intuitively, TRAcP was upregulated by metformin, which was also seen with 0.2 mM in the cocultures. This could indicate that metformin diversely affects the transcription of osteoclast genes: DC-STAMP and Cathepsin K were downregulated whereas TRAcP was upregulated, which is different from our previous work on mouse osteoclasts, where upregulation of all osteoclast genes was similar (De Vries et al., 2009). TRAcP is also expressed by the osteoclast's mononuclear family members, macrophages and dendritic cells. Here, TRAcP may be of importance in bacterial clearance and general functionality of macrophages and dendritic cells (Haymon 2008). It is therefore feasible that metformin shifts the differentiation of monocytes towards macrophages and dendritic cells.

Concerning the balance of strong and weaker points of this study, we show with two assays that osteoclast formation and osteoclast activity are inhibited by metformin. 1) Metformin inhibited cell-cell mediated osteoclastogenesis, with the identification of various PDL related genes that are downregulated (M-CSF, RANKL). 2) In assays using only osteoclast CD14 precursors, it was shown that also in this "pure" system, osteoclast formation and activity is inhibited, concomitant with down regulation of RANK and Cathepsin K. A weak point in our study is that, although metformin did not interfere with cell numbers of periodontal ligament fibroblasts, it is not clear whether metformin may also induce secreted osteoclastogenesis inhibitory molecules. Also, the possible effects of metformin on the energy metabolism, such as in osteoclasts, needs further investigation.

Anti-aging has recently been added to the long list of metformin's pleotropic effects (Hu et al., 2021; Mohammed et al., 2021). Increase in osteoclasts and osteoclastic activity can be seen as a result of aging, especially as a result of menopause. The present study therefore could add antiosteoclast formation as one of the aspects of anti-aging. Metformin influence both the orchestrator of osteoclastogenesis, the periodontal ligament fibroblast, as well as the monocyte osteoclast precursor. Our results, summarized in Figure 6, illustrate that the alleged bone sparing mechanism of metformin could be due to inhibiting osteoclasts, rather than, or in parallel with increased osteogenesis.

REFERENCES

- Apostolova, N., Iannantuoni, F., Gruevska, A., Muntane, J., Rocha, M., and Victor, V. M. (2020). Mechanisms of Action of Metformin in Type 2 Diabetes: Effects on Mitochondria and Leukocyte-Endothelium Interactions. *Redox Biol.* 34, 101517. doi:10.1016/j.redox.2020.101517
- Araújo, A. A., Pereira, A. S. B. F., Medeiros, C. A. C. X., Brito, G. A. C., Leitão, R. F. C., Araújo, L. S., et al. (2017). Effects of Metformin on Inflammation, Oxidative Stress, and Bone Loss in a Rat Model of Periodontitis. *PLoS One* 12, e0183506. doi:10.1371/journal.pone.0183506

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

All the individuals were informed that the cells retrieved from the surgical waste material was used for research on bone formation and bone degradation. A signed informed consent and samples were coded to guarantee the anonymity of the donors as required by Dutch law. The use of buffy coats from the blood bank, (Sanquin, Amsterdam) was under ethical committee number NVT230.01.

AUTHOR CONTRIBUTIONS

LT, KŁ performed the experiments under guidance of TJdeV. Osteogenesis assays were assisted by JH, qPCR by TS. TF organized the collection of peridoontal ligament fibroblasts. Original idea for the study by FvdW and TJdV, AG assisted with writing. TJdV initiated writing, all authors contributed to the final manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.777450/full#supplementary-material

Supplementary Figure S1 | Titration of metformin in a mineralization assay. Periodontal ligament fibroblasts were subjected to increasing concentrations of metformin (five-fold dilutions from 1- 0.008 mM in mineralization medium. A. Effect of metformin on proliferation. DNA was measured at t=0, (C) and 0-1.0 in mineralization medium at t=14 days. #: t=0 Significantly different from all t=14 conditions, no differences between the metformin treated donor cells. B. Alkaline phosphatase per cell. C. Alizarin red staining was assessed for 3 donors after 14 and 21 days of culture. Heterogeneous staining between donors at 14 days, whereas all donors were positive at 21 days. No effects of metformin were observed. D. Micrograph of alizarin red staining, showing red, circular structures, reminiscent of nodules.

Supplementary Figure S2 | Effect of metformin on COX1 and COX2 expression. Gene expression of mitochondrial enzymes COX1 and COX2, with tendency of downregulation (n.s.)

- Bak, E. J., Park, H. G., Kim, M., Kim, S. W., Kim, S., Choi, S.-H., et al. (2010). The Effect of Metformin on Alveolar Bone in Ligature-Induced Periodontitis in Rats: a Pilot Study. J. Periodontol. 81, 412–419. doi:10.1902/jop.2009.090414
- Bastidas-Coral, A. P., Bakker, A. D., Zandieh-Doulabi, B., Kleverlaan, C. J., Bravenboer, N., Forouzanfar, T., et al. (2016). Cytokines TNF-α, IL-6, IL-17F, and IL-4 Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells. *Stem Cell Int* 2016, 1318256. doi:10.1155/2016/1318256
- Bloemen, V., Schoenmaker, T., De Vries, T. J., and Everts, V. (2010). Direct Cell-Cell Contact between Periodontal Ligament Fibroblasts and Osteoclast Precursors Synergistically Increases the Experession Ofgenes Related to Osteoclastogenesis. J. Cel Physiol. 222, 565–573. doi:10.1002/jcp.21971

- Cao, Y., Jansen, I. D. C., Sprangers, S., De Vries, T. J., and Everts, V. (2017). TNF-α Has Both Stimulatory and Inhibitory Effects on Mouse Monocyte-Derived Osteoclastogenesis. J. Cel Physiol. 232, 3273–3285. doi:10.1002/ jcp.26024
- Cao, Y., Jansen, I. D., Sprangers, S., Stap, J., Leenen, P. J., Everts, V., et al. (2016). ILlbeta Differently Stimulates Proliferation and Multinucleation of Distinct Mouse Bone Marrow Osteoclast Precursor Subsets. J. Leukoc. Biol. 100, 513–523. doi:10.1189/jlb.1A1215-543R
- Chandran, M. (2017). Diabetes Drug Effects on the Skeleton. *Calcif Tissue Int.* 100, 133–149. doi:10.1007/s00223-016-0203-x
- De Vries, T. J., Schoenmaker, T., Hooibrink, B., Leenen, P. J. M., and Everts, V. (2009). Myeloid Blasts Are the Mouse Bone Marrow Cells Prone to Differentiate into Osteoclasts. J. Leukoc. Biol. 85, 919–927. doi:10.1189/ jlb.0708402
- De Vries, T. J., Schoenmaker, T., Micha, D., Hogervorst, J., Bouskla, S., Forouzanfar, T., et al. (2017). Periodontal Ligament Fibroblasts as a Cell Model to Study Osteogenesis and Osteoclastogenesis in Fibrodysplasia Ossificans Progressiva. *Bone* 109, 168–177. doi:10.1016/j.bone.2017.07.007
- De Vries, T. J., Schoenmaker, T., Van Veen, H. A., Hogervorst, J., Krawczyk, P. M., Moonen, C. G. J., et al. (2019). The Challenge of Teaching Essential Immunology Laboratory Skills to Undergraduates in One Month-Experience of an Osteoimmunology Course on TLR Activation. *Front. Immunol.* 10, 1822. doi:10.3389/fimmu.2019.01822
- De Vries, T. J., Schoenmaker, T., Wattanaroonwong, N., van den Hoonaard, M., Beertsen, W., and Everts, V. (2006). Gingival Fibroblasts Are Better at Inhibiting Osteoclast Formation Than Periodontal Ligament Fibroblasts. J. Cel. Biochem. 98, 370–382. doi:10.1002/jcb.20795
- De Vries, T. J., Yousovich, J., Schoenmaker, T., Scheres, N., and Everts, V. (2016). Tumor Necrosis Factor-α Antagonist Infliximab Inhibits Osteoclast Formation of Peripheral Blood Mononuclear Cells but Does Not Affect Periodontal Ligament Fibroblast-Mediated Osteoclast Formation. J. Periodont Res. 51, 186–195. doi:10.1111/jre.12297
- Fan, K.-J., Wu, J., Wang, Q.-S., Xu, B.-X., Zhao, F.-T., and Wang, T.-Y. (2020). Metformin Inhibits Inflammation and Bone Destruction in Collagen-Induced Arthritis in Rats. Ann. Transl Med. 8, 1565. doi:10.21037/atm-20-3042
- Groeneveld, M. C., Everts, V., and Beertsen, W. (1995). Alkaline Phosphatase Activity in the Periodontal Ligament and Gingiva of the Rat Molar: its Relation to Cementum Formation. J. Dent. Res. 74, 1374–1381. doi:10.1177/ 00220345950740070901
- Halimi, S. (2006). Metformin: 50 Years Old, Fit as a Fiddle, and Indispensable for its Pivotal Role in Type 2 Diabetes Management. *Diabetes Metab.* 32, 555–556. doi:10.1016/s1262-3636(07)70309-9
- Haymon, A. R. (2008). Tartrate-acid Phosphatase (TRAP) and the Osteoclast/ immune Cell Dichotomy. Autoimmunity 41, 218–223. doi:10.1080/ 08916930701694667
- Hu, D., Xie, F., Xiao, Y., Lu, C., Zhong, J., Huang, D., et al. (2021). Metformin: A Potential Candidate for Targeting Aging Mechanisms. *Aging Dis.* 12, 480–493. doi:10.14336/ad.2020.0702
- Jia, L., Xiong, Y., Zhang, W., Ma, X., and Xu, X. (2020). Metformin Promotes Osteogenic Differentiation and Protects against Oxidative Stress-Induced Damage in Periodontal Ligament Stem Cells via Activation of the Akt/Nrf2 Signaling Pathway. *Exp. Cel Res.* 386, 111717. doi:10.1016/ j.yexcr.2019.111717
- Kang, W., Wang, T., Hu, Z., Liu, F., Sun, Y., and Ge, S. (2017). Metformin Inhibits Porphyromonas Gingivalis Lipopolysaccharide-Influenced Inflammatory Response in Human Gingival Fibroblasts via Regulating Activating Transcription Factor-3 Expression. J. Periodontol. 88, e169–e178. doi:10.1902/jop.2017.170168
- Karlis, G. D., Schöningh, E., Jansen, I. D. C., Schoenmaker, T., Hogervorst, J. M. A., Van Veen, H. A., et al. (2020). Chronic Exposure of Gingival Fibroblasts to TLR2 or TLR4 Agonist Inhibits Osteoclastogenesis but Does Not Affect Osteogenesis. *Front. Immunol.* 11, 1693. doi:10.3389/ fmmu.2020.01693
- Kong, Y. Y., Boyle, W. J., and Penninger, J. M. (1999). Osteoprotegerin Ligand: a Common Link between Osteoclastogenesis, Lymph Node Formation and Lymphocyte Development. *Immunol. Cel Biol* 77, 188–193. doi:10.1046/ j.1440-1711.1999.00815.x

- Kurian, I. G., Dileep, P., Ipshita, S., and Pradeep, A. R. (2018). Comparative Evaluation of Subgingivally-Delivered 1% Metformin and Aloe Vera Gel in the Treatment of Intrabony Defects in Chronic Periodontitis Patients: A Randomized, Controlled Clinical Trial. J. Investig. Clin. Dent 9, e12324. doi:10.1111/jicd.12324
- Loo-Kirana, R., Gilijamse, M., Hogervorst, J., Schoenmaker, T., and De Vries, T. J. (2021). Although Anatomically Micrometers Apart: Human Periodontal Ligament Cells Are Slightly More Active in Bone Remodeling Than Alveolar Bone Derived Cells. Front. Cel Develop. Biol. 9, 709408. doi:10.3389/fcell.2021.709408
- Mai, Q.-G., Zhang, Z.-M., Xu, S., Lu, M., Zhou, R.-P., Zhao, L., et al. (2011). Metformin Stimulates Osteoprotegerin and Reduces RANKL Expression in Osteoblasts and Ovariectomized Rats. J. Cel. Biochem. 112, 2902–2909. doi:10.1002/jcb.23206
- Mohammed, I., Hollenberg, M. D., Ding, H., and Triggle, C. R. (2021). A Critical Review of the Evidence that Metformin Is a Putative Anti-aging Drug that Enhances Healthspan and Extends Lifespan. *Front. Endocrinol.* 12, 718942. doi:10.3389/fendo.2021.718942
- Moonen, C. G. J., Alders, S. T., Bontkes, H. J., Schoenmaker, T., Nicu, E. A., Loos, B. G., et al. (2018). Survival, Retention, and Selective Proliferation of Lymphocytes Is Mediated by Gingival Fibroblasts. *Front. Immunol.* 9, 1725. doi:10.3389/ fimmu.2018.01725
- Nascimento, G. G., Leite, F. R. M., Vestergaard, P., Scheutz, F., and López, R. (2018). Does Diabetes Increase the Risk of Periodontitis? A Systematic Review and Meta-Regression Analysis of Longitudinal Prospective Studies. *Acta Diabetol.* 55, 653–667. doi:10.1007/s00592-018-1120-4
- Park-Min, K.-H. (2019). Metabolic Reprogramming in Osteoclasts. Semin. Immunopathol 41, 565–572. doi:10.1007/s00281-019-00757-0
- Pradeep, A. R., Nagpal, K., Karvekar, S., Patnaik, K., Naik, S. B., and Guruprasad, C. N. (2015). Platelet-rich Fibrin with 1% Metformin for the Treatment of Intrabony Defects in Chronic Periodontitis: a Randomized Controlled Clinical Trial. J. Periodontol. 86, 729–737. doi:10.1902/jop.2015.140646
- Pradeep, A. R., Patnaik, K., Nagpal, K., Karvekar, S., Guruprasad, C. N., and Kumaraswamy, K. M. (2017). Efficacy of 1% Metformin Gel in Patients with Moderate and Severe Chronic Periodontitis: A Randomized Controlled Clinical Trial. J. Periodontol. 88, 1023–1029. doi:10.1902/ jop.2017.150096
- Pradeep, A. R., Patnaik, K., Nagpal, K., Karvekar, S., Ramamurthy, B. L., Naik, S. B., et al. (2016). Efficacy of Locally-Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Patients with Chronic Periodontitis: a Randomized, Controlled Clinical Trial. J. Investig. Clin. Dent 7, 239–245. doi:10.1111/ jicd.12150
- Pradeep, A. R., Rao, N. S., Naik, S. B., and Kumari, M. (2013). Efficacy of Varying Concentrations of Subgingivally Delivered Metformin in the Treatment of Chronic Periodontitis: a Randomized Controlled Clinical Trial. J. Periodontol. 84, 212–220. doi:10.1902/jop.2012.120025
- Rao, N. S., Pradeep, A. R., Kumari, M., and Naik, S. B. (2013). Locally Delivered 1% Metformin Gel in the Treatment of Smokers with Chronic Periodontitis: a Randomized Controlled Clinical Trial. *J. Periodontol.* 84, 1165–1171. doi:10.1902/jop.2012.120298
- Ren, Y., Han, X., Ho, S. P., Harris, S. E., Cao, Z., Economides, A. N., et al. (2015). Removal of SOST or Blocking its Product Sclerostin Rescues Defects in the Periodontitis Mouse Model. *FASEB J.* 29, 2702–2711. doi:10.1096/fj.14-265496
- Ruppeka-Rupeika, E., Hogervorst, J., Wouters, F., Schoenmaker, T., Forouzanfar, T., and De Vries, T. J. (2018). Osteogenic and Osteoclastogenic Potential of Jaw Bone-Derived Cells-A Case Study. J. Cel Biochem 119, 5391–5401. doi:10.1002/ jcb.26690
- Sokos, D., Everts, V., and De Vries, T. J. (2015). Role of Periodontal Ligament Fibroblasts in Osteoclastogenesis: a Review. J. Periodont Res. 50, 152–159. doi:10.1111/jre.12197
- Son, H. J., Lee, J., Lee, S. Y., Kim, E. K., Park, M. J., Kim, K. W., et al. (2014). Metformin Attenuates Experimental Autoimmune Arthritis through Reciprocal Regulation of Th17/Treg Balance and Osteoclastogenesis. *Mediators Inflamm.* 2014, 973986. doi:10.1155/2014/973986
- Sprangers, S., Schoenmaker, T., Cao, Y., Everts, V., and De Vries, T. J. (2016). Different Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to IL-17A. J. Cel. Physiol 231, 1249–1260. doi:10.1002/jcp.25220

- Sun, J., Du, J., Feng, W., Lu, B., Liu, H., Guo, J., et al. (2017). Histological Evidence that Metformin Reverses the Adverse Effects of Diabetes on Orthodontic Tooth Movement in Rats. J. Mol. Hist. 48, 73–81. doi:10.1007/s10735-016-9707-y
- Ten Harkel, B., Schoenmaker, T., Picavet, D. I., Davison, N. L., De Vries, T. J., and Everts, V. (2015). The Foreign Body Giant Cell Cannot Resorb Bone, but Dissolves Hydroxyapatite like Osteoclasts. *Plos. ONE* 10, e0139564. doi:10.1371/journal.pone.0139564
- Ursini, F., Russo, E., Pellino, G., D'Angelo, S., Chiaravalloti, A., De Sarro, G., et al. (2018). Metformin and Autoimmunity: A "New Deal" of an Old Drug. Front. Immunol. 9, 1236. doi:10.3389/fimmu.2018.01236
- Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A., and Teeuw, W. J. (2019). Evaluating All Potential Oral Complications of Diabetes Mellitus. *Front. Endocrinol.* 10, 56. doi:10.3389/fendo.2019.00056
- Weivoda, M. M., Chew, C. K., Monroe, D. G., Farr, J. N., Atkinson, E. J., Geske, J. R., et al. (2020). Identification of Osteoclast-Osteoblast Coupling Factors in Humans Reveals Links between Bone and Energy Metabolism. *Nat. Commun.* 11, 87. doi:10.1038/s41467-019-14003-6
- Wu, Y.-Y., Xiao, E., and Graves, D. T. (2015). Diabetes Mellitus Related Bone Metabolism and Periodontal Disease. Int. J. Oral Sci. 7, 63–72. doi:10.1038/ijos.2015.2
- Zamri, F., and De Vries, T. J. (2020). Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both. *Front. Immunol.* 11, 591365. doi:10.3389/ fmmu.2020.591365

Zhao, Z., Liu, J., Schneider, A., Gao, X., Ren, K., Weir, M. D., et al. (2019). Human Periodontal Ligament Stem Cell Seeding on Calcium Phosphate Cement Scaffold Delivering Metformin for Bone Tissue Engineering. J. Dentistry 91, 103220. doi:10.1016/j.jdent.2019.103220

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tao, Łagosz-Ćwik, Hogervorst, Schoenmaker, Grabiec, Forouzanfar, van der Weijden and de Vries. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.